New scan may spot hidden heart harm in childhood cancer survivors
NCT ID NCT01671696
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at 80 childhood cancer survivors who had received high doses of anthracycline chemotherapy. Researchers used cardiac MRI and blood tests to find early signs of heart damage that standard tests might miss. The goal was to see if these advanced methods could detect hidden heart problems before symptoms appear, potentially allowing earlier treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better ways to detect heart damage early in childhood cancer survivors, potentially preventing heart failure.
- What could go wrong
- This is an observational study, not a treatment trial. The findings may not lead to new therapies, and the small size (80 participants) limits how widely results can be applied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
80 people
The number who actually took part.
- Started
-
Nov 2011
- Finished
-
Oct 2017
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Survivors of childhood cancer who were treated with anthracyclines and are greater than 2 years from their last cycle of chemotherapy
- Ages
-
9 to 35 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
5.1 A. Subject Inclusion Criteria * Childhood cancer survivors from the late effect clinic who had received ≥240 mg/m2 anthracyclines, been in complete remission and off chemotherapy for a minimum of 2 years. * Age \> 9 years of age\* * Parental/caregiver consent and subject assent to enrollment \* Age \> 9 years of age was chosen to avoid the need for general anesthesia or sedation B. Subject Inclusion Criteria * Enrolled in part A of the study, which took place from October 2011 to July 2013. * Parental/caregiver consent and subject assent to enrollment C. Subject Inclusion Criteria * Childhood cancer survivors from the late effect clinic who had received \< 300 mg/m2 anthracyclines, been in complete remission and off chemotherapy for a minimum of 1 year * Age ≥ 9 years of age\* * Parental/caregiver consent and subject assent to enrollment * \* Age \> 9 years of age was chosen to avoid the need for general anesthesia or sedation 5.2 A. Subject Exclusion Criteria * Contraindications to CMRI.\* * Pregnancy\*\* \* Contraindications to CMRI (i.e., magnetically activated implants/devices; cardiac pacemaker or wires; after the patients are scheduled for CMRI, they will be sent our standard pre-MRI paperwork/questionnaire, to determine eligibility to have an MRI) \*\*If a female patient of child bearing age is not sure if they are pregnant or not, as part of the standard CMRI with contrast procedures, a urine pregnancy test will be done. If the result is positive the subject will not be allowed to continue in the study. CMRI with gadolinium may affect a fetus, and also the CMRI results are an integral part of this research study. * Orbital X-Ray confirmed to have metal in the eye or patient confirmed to have metal in the eye. B. Subject Exclusion Criteria * Not enrolled in part A of the study * Contraindications to CMRI\* * Pregnancy \*\* * Orbital X-Ray confirmed to have metal in the eye or patient confirmed to have metal in the eye * C. Subject Exclusion Criteria * Total Cumulative dose anthracyclines ≥300 mg/m2 * Contraindications to CMRI\* * Pregnancy \*\* * Orbital X-Ray confirmed to have metal in the eye or patient confirmed to have metal in the eye Exclusion Criteria: * Contraindications to CMRI * Relapse of their cancer * Pregnancy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cardiovascular disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Connecticut Children's Medical Center
Hartford, Connecticut, 06106, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Tailored heat warnings shield chronic disease patients from dangerous temperatures?
- Why do children with cancer feel pain differently? study compares pain sensitivity and activity
- Can a phone app help childhood cancer survivors keep track of their health?
- Can a picture tool help kids with cancer say how they feel?
- Game-Based app aims to boost HPV vaccination in young cancer survivors
- Can calming inflammation shield the heart?